BAF-MM20R-100μg / 询价
BAF-MM20R-500μg / 询价
BAF-MM20R-500μgx2 / 询价
Mouse BAFFR/TNFRSF13C Protein
Recombinant Mouse BAFFR/TNFRSF13C Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Ser10-Ala71.[Accession | Q9D8D0-1]
The protein has a predicted MW of 33.5 kDa. Due to glycosylation, the protein migrates to 35-45 kDa based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Mouse BAFFR on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of Mouse BAFFR is greater than 95% as determined by SEC-HPLC.
Immobilized Human BAFF (Trimer), His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Mouse BAFFR, hFc Tag with the EC50 of 18.4ng/ml determined by ELISA (QC test).
Immobilized Mouse BAFF, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Mouse BAFFR, hFc Tag with the EC50 of 5.9ng/ml determined by ELISA.
BAFF binds to three TNF receptor superfamily members: B-cell maturation antigen (BCMA/TNFRSF17), transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI/TNFRSF13B) and BAFF receptor (BAFF R/BR3/TNFRSF13C). These receptors are type III transmembrane proteins that lack a signal peptide. Whereas TACI and BCMA bind BAFF and another TNF superfamily ligand, APRIL (a proliferation-inducing ligand), BAFF R selectively binds BAFF.
CD268; BAFFR; BR3; TNFRSF13C; BROMIX; CVID4; prolixin
(1)Tin K , Peng C , Christopher T , et al. BAFF Receptor mAb Treatment Ameliorates Development and Progression of Atherosclerosis in Hyperlipidemic ApoE?/? Mice[J]. PLoS ONE, 2013, 8(4):e60430-.
